The diagnosis of spinal muscular atrophy (SMA), especially Type 1, is a medical emergency, as SMA is a leading genetic cause of death in infants. In infants with SMA Type 1, the onset of irreversible denervation occurs within the first 3 months with loss of 90% of motor units occurring within 6 months of age.
This supplement examines the clinical implications of delayed diagnosis of SMA, as well as assessment tools, treatment methods, and resources that are available for physicians, patients, and caregivers to better manage this rare disease.
The diagnosis of spinal muscular atrophy (SMA), especially Type 1, is a medical emergency, as SMA is a leading genetic cause of death in infants. In infants with SMA Type 1, the onset of irreversible denervation occurs within the first 3 months with loss of 90% of motor units occurring within 6 months of age.
This supplement examines the clinical implications of delayed diagnosis of SMA, as well as assessment tools, treatment methods, and resources that are available for physicians, patients, and caregivers to better manage this rare disease.
The diagnosis of spinal muscular atrophy (SMA), especially Type 1, is a medical emergency, as SMA is a leading genetic cause of death in infants. In infants with SMA Type 1, the onset of irreversible denervation occurs within the first 3 months with loss of 90% of motor units occurring within 6 months of age.
This supplement examines the clinical implications of delayed diagnosis of SMA, as well as assessment tools, treatment methods, and resources that are available for physicians, patients, and caregivers to better manage this rare disease.
The ideas and opinions expressed in Best of 2019 – The RA Report: Top News Highlights do not necessarily reflect those of the publisher. Frontline Medical Communications will not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this publication, including any claims related to the products, drugs, or services mentioned herein.
The ideas and opinions expressed in Best of 2019 – The RA Report: Top News Highlights do not necessarily reflect those of the publisher. Frontline Medical Communications will not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this publication, including any claims related to the products, drugs, or services mentioned herein.
The ideas and opinions expressed in Best of 2019 – The RA Report: Top News Highlights do not necessarily reflect those of the publisher. Frontline Medical Communications will not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this publication, including any claims related to the products, drugs, or services mentioned herein.
Claudia A. Chiriboga, MD, MPH, FAAN (Program Chair) Professor of Neurology and Pediatrics at CUIMC Division of Pediatric Neurology Columbia University Irving Medical Center New York, NY
Diana P. Castro, MD Assistant Professor Pediatrics and Neurology Neurotherapeutics UT Southwestern Medical Center Neurologist Children’s Health Dallas, TX
Mary Schroth, MD Chief Medical Officer Cure SMA Elk Grove Village, IL
Charlotte J. Sumner, MD Professor of Neurology and Neuroscience Johns Hopkins University School of Medicine Baltimore, MD
Kathryn J. Swoboda, MD Katherine B. Sims, MD, Endowed Chair in Neurogenetics Director, Neurogenetics Program Mass General Hospital for Children Boston, MA
Sponsor
This supplement is sponsored by Genentech, a member of the Roche Group.
Claudia A. Chiriboga, MD, MPH, FAAN (Program Chair) Professor of Neurology and Pediatrics at CUIMC Division of Pediatric Neurology Columbia University Irving Medical Center New York, NY
Diana P. Castro, MD Assistant Professor Pediatrics and Neurology Neurotherapeutics UT Southwestern Medical Center Neurologist Children’s Health Dallas, TX
Mary Schroth, MD Chief Medical Officer Cure SMA Elk Grove Village, IL
Charlotte J. Sumner, MD Professor of Neurology and Neuroscience Johns Hopkins University School of Medicine Baltimore, MD
Kathryn J. Swoboda, MD Katherine B. Sims, MD, Endowed Chair in Neurogenetics Director, Neurogenetics Program Mass General Hospital for Children Boston, MA
How prepared are you to recognize and meet the needs of patients with spinal muscular atrophy?
Learn more about spinal muscular atrophy in this supplement to Pediatric News.
Claudia A. Chiriboga, MD, MPH, FAAN (Program Chair) Professor of Neurology and Pediatrics at CUIMC Division of Pediatric Neurology Columbia University Irving Medical Center New York, NY
Diana P. Castro, MD Assistant Professor Pediatrics and Neurology Neurotherapeutics UT Southwestern Medical Center Neurologist Children’s Health Dallas, TX
Mary Schroth, MD Chief Medical Officer Cure SMA Elk Grove Village, IL
Charlotte J. Sumner, MD Professor of Neurology and Neuroscience Johns Hopkins University School of Medicine Baltimore, MD
Kathryn J. Swoboda, MD Katherine B. Sims, MD, Endowed Chair in Neurogenetics Director, Neurogenetics Program Mass General Hospital for Children Boston, MA
Rare cancers, though individually rare by definition, represent almost a quarter of the total adult cancer burden when grouped together. Few traditional trials exist for these patients, many physicians know little about such tumors, and approved therapies are limited or nonexistent. The 2019 Rare Cancers Special Report features interviews with those who are leading the charge in affecting change on the rare cancer front, as well as reports on NCI-MATCH and the DART trial, and other resources for physicians and patients.
Rare cancers, though individually rare by definition, represent almost a quarter of the total adult cancer burden when grouped together. Few traditional trials exist for these patients, many physicians know little about such tumors, and approved therapies are limited or nonexistent. The 2019 Rare Cancers Special Report features interviews with those who are leading the charge in affecting change on the rare cancer front, as well as reports on NCI-MATCH and the DART trial, and other resources for physicians and patients.
Rare cancers, though individually rare by definition, represent almost a quarter of the total adult cancer burden when grouped together. Few traditional trials exist for these patients, many physicians know little about such tumors, and approved therapies are limited or nonexistent. The 2019 Rare Cancers Special Report features interviews with those who are leading the charge in affecting change on the rare cancer front, as well as reports on NCI-MATCH and the DART trial, and other resources for physicians and patients.
Reducing Cardiovascular Events in Patients with Type 2 Diabetes Mellitus
This supplement offers the opportunity to earn a total of 1 CME credit.
Credit is awarded for successful completion of the online evaluation at the link below. This link may also be found within the supplement on the first page of the article.
To receive CME credit, please read the journal article and, upon completion, go to www.pceconsortium.org/CVEvents to complete the online post-test and receive your certificate of credit.
Sponsor
This supplement was sponsored by Primary Care Education Consortium and Primary …
Reducing Cardiovascular Events in Patients with Type 2 Diabetes Mellitus
This supplement offers the opportunity to earn a total of 1 CME credit.
Credit is awarded for successful completion of the online evaluation at the link below. This link may also be found within the supplement on the first page of the article.
To receive CME credit, please read the journal article and, upon completion, go to www.pceconsortium.org/CVEvents to complete the online post-test and receive your certificate of credit.
Reducing Cardiovascular Events in Patients with Type 2 Diabetes Mellitus
This supplement offers the opportunity to earn a total of 1 CME credit.
Credit is awarded for successful completion of the online evaluation at the link below. This link may also be found within the supplement on the first page of the article.
To receive CME credit, please read the journal article and, upon completion, go to www.pceconsortium.org/CVEvents to complete the online post-test and receive your certificate of credit.
The Rare Rheumatologic Diseases Special Report is a supplement to Rheumatology News, providing readers with information about how registries for rare pediatric diseases such as polyarticular juvenile idiopathic arthritis, scleroderma, and myositis, have led to important insights into treatments and disease characteristics. The issue also discusses updated recommendations on the management of large-vessel vasculitis from the European League Against Rheumatism and recent efforts to establish classification criteria for chronic nonbacterial osteomyelitis/chronic recurrent multifocal osteomyelitis.
The Rare Rheumatologic Diseases Special Report is a supplement to Rheumatology News, providing readers with information about how registries for rare pediatric diseases such as polyarticular juvenile idiopathic arthritis, scleroderma, and myositis, have led to important insights into treatments and disease characteristics. The issue also discusses updated recommendations on the management of large-vessel vasculitis from the European League Against Rheumatism and recent efforts to establish classification criteria for chronic nonbacterial osteomyelitis/chronic recurrent multifocal osteomyelitis.
The Rare Rheumatologic Diseases Special Report is a supplement to Rheumatology News, providing readers with information about how registries for rare pediatric diseases such as polyarticular juvenile idiopathic arthritis, scleroderma, and myositis, have led to important insights into treatments and disease characteristics. The issue also discusses updated recommendations on the management of large-vessel vasculitis from the European League Against Rheumatism and recent efforts to establish classification criteria for chronic nonbacterial osteomyelitis/chronic recurrent multifocal osteomyelitis.
The Rare Pediatric Diseases Special Report is a supplement to Pediatric News that discusses advancements in the treatment of rare pediatric neuromuscular disorders like spinal muscular atrophy, Duchenne muscular dystrophy, and X-linked myotubular myopathy, as well as epileptic encephalopathies that occur in infancy and early childhood, such as West syndrome, Lennox-Gastaut syndrome, and Dravet syndrome.
The Rare Pediatric Diseases Special Report is a supplement to Pediatric News that discusses advancements in the treatment of rare pediatric neuromuscular disorders like spinal muscular atrophy, Duchenne muscular dystrophy, and X-linked myotubular myopathy, as well as epileptic encephalopathies that occur in infancy and early childhood, such as West syndrome, Lennox-Gastaut syndrome, and Dravet syndrome.
The Rare Pediatric Diseases Special Report is a supplement to Pediatric News that discusses advancements in the treatment of rare pediatric neuromuscular disorders like spinal muscular atrophy, Duchenne muscular dystrophy, and X-linked myotubular myopathy, as well as epileptic encephalopathies that occur in infancy and early childhood, such as West syndrome, Lennox-Gastaut syndrome, and Dravet syndrome.
